SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).
SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).